Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (101-110 of 627) with videos related to

Pageof 63
Sort By:
Journal of the American College of Cardiology|October 30, 2020
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk ReductionJames L Januzzi, Jialin Xu, JingWei Li, et al.
American Heart Journal|March 30, 2006
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarctionPaul W Armstrong, Kenneth W Mahaffey, Wei-Ching Chang, et al.
Clinical Cardiology|August 12, 2018
Association of Healthcare Plan with atrial fibrillation prescription patternsAndrew Young Chang, Mariam Askari, Jun Fan, et al.
Coronary Artery Disease|January 6, 2012
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarctionJames S Mills, Kenneth W Mahaffey, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|February 4, 2022
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinMuthiah Vaduganathan, Naveed Sattar, Jialin Xu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
American Journal of Nephrology|January 11, 2022
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS TrialDavid Lam, Girish N Nadkarni, Gohar Mosoyan, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 26, 2009
Influence of body mass index on the efficacy of revascularization in patients with coronary artery diseaseAslan T Turer, Kenneth W Mahaffey, Emily Honeycutt, et al.
American Heart Journal|July 31, 2013
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trialBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Pageof 63

Showing results (101-110 of 627) with videos related to

Sort By:
Pageof 63
Journal of the American College of Cardiology|October 30, 2020
Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk ReductionJames L Januzzi, Jialin Xu, JingWei Li, et al.
American Heart Journal|March 30, 2006
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarctionPaul W Armstrong, Kenneth W Mahaffey, Wei-Ching Chang, et al.
Clinical Cardiology|August 12, 2018
Association of Healthcare Plan with atrial fibrillation prescription patternsAndrew Young Chang, Mariam Askari, Jun Fan, et al.
Coronary Artery Disease|January 6, 2012
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarctionJames S Mills, Kenneth W Mahaffey, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|February 4, 2022
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to CanagliflozinMuthiah Vaduganathan, Naveed Sattar, Jialin Xu, et al.
American Heart Journal|November 2, 2013
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction studyAkshay Bagai, Paul W Armstrong, Amanda Stebbins, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
American Journal of Nephrology|January 11, 2022
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS TrialDavid Lam, Girish N Nadkarni, Gohar Mosoyan, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 26, 2009
Influence of body mass index on the efficacy of revascularization in patients with coronary artery diseaseAslan T Turer, Kenneth W Mahaffey, Emily Honeycutt, et al.
American Heart Journal|July 31, 2013
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trialBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Pageof 63